Home › NDC Lookup › Ingredients › Propofol › 00069-0248-10
💉image loading
(from DailyMed)

Propofol 10 mg/mL Injection, Emulsion — NDC 0069-0248-10 (Billing 00069-0248-10)

by Pfizer Laboratories Div Pfizer Inc · 10 VIAL in 1 CARTON / 100 mL in 1 VIAL

This is a package of Propofol 10 mg/mL Injection, Emulsion from Pfizer Laboratories Div Pfizer Inc, marketed since Oct 2020 and currently FDA-listed. It is this product's only package size.

NDC 00069-0248-10
🏷️ FDA NDC (as labeled) 0069-0248-10 billing pads the labeler segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 0069-0248-10 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0069 labeler · 0248 product · 10 package
Package marketed since
Oct 5, 2020
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 0069024810 3
Medicaid fills, this package
1,825 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0069-0248-10
Product NDC 0069-0248
11-digit billing NDC 00069024810
NCPDP billing unit ML — per mL (volume)
Application # ANDA205576
SPL Set ID 5701fd0d-b178-4d52-a6c5-ba78f74d645c
Established class (EPC) General Anesthetic
Physiologic effect General Anesthesia
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-10-05
Route INTRAVENOUS
Dosage form INJECTION, EMULSION
Substance PROPOFOL
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 016796
GCN 14021
HICL code 004842
Ingredient (HICL) Propofol In Lipid Emulsions
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H2
Therapeutic class — intermediate (HIC2) Psychoactive Drugs
HIC3 code H2C
Therapeutic class — specific (HIC3) General Anesthetics,Injectable
AHFS code 28:04.08.00
AHFS class Non-Barbiturates
FDB label name PROPOFOL 1,000 MG/100 ML VIAL
FDB brand name Propofol
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 016796
  • GCN: 14021
  • HICL (First Databank): 004842
  • AHFS class code: 28:04.08.00
Why two NDCs? The FDA registers this code as 0069-0248-10 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00069-0248-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name PROPOFOL 1,000 MG/100 ML VIAL Ingredient Propofol In Lipid Emulsions
📖 What it is MedlinePlus · NLM

Propofol is used to begin and maintain general anesthesia (you are unconscious and unaware of what is happening) during surgery in adults and children. It is also used to provide sedation (you are relaxed, sleepy or in some cases asleep) in adults during surgical or other medical procedures. Propofol is also used to provide sedation for adults in intensive care units that are receiving mechanical ventilation (a machine that takes over the work of breathing). Propofol is in a class of medications called anesthetic agents. It works by changing the activity of certain substances in the brain.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Propofol is given through a vein to put you under general anesthesia or to provide sedation during procedures. It is also used to sedate adults in the ICU who are on a breathing ma...
  • Some people feel burning, stinging, or pain at the IV site, and this is one of the more common effects. Your team can reduce it by using a larger vein or giving lidocaine first. An...
  • Low blood pressure, a slower heart rate, and a short pause in breathing are the most common. Your team watches for these and treats them. You may also get a rash, itching, or invol...
  • Yes. Tell them if you have ever had a severe allergic reaction to eggs, egg products, soybeans, or soy products, because propofol should not be used in that case. Also mention epil...
📖 Read our full Propofol guide →
1
Nutrient depletion considerations

Propofol may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo $0.8744 $874.40 / 1000 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Medicare Part B allowsASP · J2704 $0.089 / J2704 unit —
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)0069-0248-10
11-digit billing NDC00069-0248-10
Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)
HCPCS J-codeJ2704
DescriptorINJECTION, PROPOFOL, 10 MG
Billing units / pkg1 units
How the units are derivedThis package is 100 ML; the HCPCS unit is 10 MG, so one package = 1 billing unit.
Medicare Part B spend (2026 (Q1))$20,183 · 7,494 claims · $2.69 per claim (all NDCs under J2704)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00069-0248-10 You're viewing this Main listing 10 VIAL in 1 CARTON / 100 mL in 1 VIAL 2020-10-05 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
propofol 10 mg/mL 25021-0608-20 Sagent 25 vials $0.171 AB Availability likely —
propofol 10 mg/mL 71288-0730-51 Meitheal 10 vials $0.171 AB Availability likely —
Propofol 10 mg/mL 00409-6010-25 Hospira, 25 vials $0.171 AB Availability likely —
Propofol 10 mg/mL 00409-1511-98 Hospira, 25 vials $0.171 AB Availability likely —
Propofol 10 mg/mLthis 00069-0248-10 Pfizer 10 vials — AB FDA listed —
Propofol 10 mg/mL 00409-4699-24 Hospira, 10 vials — AB FDA listed —
Propofol 10 mg/mL 00641-6196-10 Hikma 10 vials — AB FDA listed —
propofol 10 mg/mL 16714-0690-10 NorthStar 10 vials — AB FDA listed —
propofol 10 mg/mL 23155-0345-41 Heritage 10 vials — AB FDA listed —
Propofol Injectable Emulsion 10 mg/mL 43598-0549-10 Dr. 10 vials — AB FDA listed —
Propofol 10 mg/mL 51662-1470-01 HF 100 ml — AB FDA listed —
Diprivan 10 mg/mL 63323-0269-59 Fresenius 20 vials — AB FDA listed —
propofol 10 mg/mL 71288-0731-53 Meitheal 10 vials — AB FDA listed —
Propofol 10 mg/mL 72572-0612-10 Civica, 10 vials — AB FDA listed —
Propofol 10 mg/mL 80830-2365-07 Amneal 10 vials — AB FDA listed —
Propofol 10 mg/mL 83634-0603-20 Avenacy, 20 vials — AB FDA listed —
Propofol 10 mg/mL 00641-6194-10 Hikma 10 vials — AB FDA listed —
Propofol 10 mg/mL 00641-6195-20 Hikma 20 vials — AB FDA listed —
Propofol 10 mg/mL 51662-1293-01 HF 20 ml — AB FDA listed —
Propofol 10 mg/mL 00069-0234-20 Pfizer 20 vials — AB FDA listed —
Propofol 10 mg/mL 51662-1471-01 HF 50 ml — AB FDA listed —
Propofol 10 mg/mL 00069-0209-10 Pfizer 10 vials — AB FDA listed —
Propofol 10 mg/mL 72572-0590-10 Civica, 10 vials — AB FDA listed —
propofol 10 mg/mL 71288-0729-21 Meitheal 10 vials — AB FDA listed —
Propofol 10 mg/mL 80830-2364-08 Amneal 20 vials — AB FDA listed —
Diprivan 10 mg/mL 65219-0800-10 Fresenius 10 vials — AB FDA listed —
Propofol 10 mg/mL 80830-1188-07 Amneal 10 vials — AB FDA listed —
propofol 10 mg/mL 16714-0977-20 NorthStar 20 vials — AB FDA listed —
Propofol 10 mg/mL 72572-0601-20 Civica, 20 vials — AB FDA listed —
propofol 10 mg/mL 16714-0528-10 NorthStar 10 vials — AB FDA listed —
Propofol 10 mg/mL 83854-0018-10 Anthea 10 vials — AB FDA listed —
Propofol 10 mg/mL 00409-0501-98 Hospira, 20 vials — AB FDA listed —
Propofol 10 mg/mL 00409-0010-98 Hospira, 10 vials — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Oct 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Propofol inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPfizer Laboratories Div Pfizer Inc
Application holderINNOPHARMA LICENSING LLC A SUB OF PFIZER INC
FDA applicationANDA205576 (ANDA)
Labeler code00069
First marketedOct 2020
Product typeHuman Prescription Drug
Portfolio242 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.8K
Units reimbursed last 4 qtrs
108.2K
Gross reimbursed last 4 qtrs
$94.6K
Avg / prescription
$51.83
Avg / unit
$0.8744
Latest quarter Q1 2026
112Rx
Fee-for-service vs managed care ⓘ
94% MCO
Fee-for-service · 111 Rx Managed care · 1,714 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: 4,316 units · 220 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 730 units · 12.7 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 33,849 units · 173 per 100k residents NY Vermont: 38 units · 5.9 per 100k residents VT New Hampshire: no data reported NH Oregon: 900 units · 21.3 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 1,300 units · 40.5 per 100k residents IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 920 units · 7.8 per 100k residents OH Pennsylvania: 39,395 units · 304 per 100k residents PA New Jersey: 2,562 units · 27.6 per 100k residents NJ Massachusetts: no data reported MA California: 4,238 units · 10.9 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 2,500 units · 28.7 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 3,300 units · 46.3 per 100k residents TN North Carolina: 9,100 units · 84.0 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 5,040 units · 22.3 per 100k residents FL
Units reimbursed · per 100k residents
5.9304
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Pennsylvania 304 /100k
2 Idaho 220 /100k
3 New York 173 /100k
4 North Carolina 84.0 /100k
5 Tennessee 46.3 /100k
6 Iowa 40.5 /100k
7 Virginia 28.7 /100k
8 New Jersey 27.6 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk ✓ Available
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Pfizer Laboratories Div Pfizer Inc. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Pfizer Laboratories Div Pfizer Inc is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code J2704 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.